The US 2014 patent for conditions for which NNZ-2591 may be suitable was somewhat speculative (although agreed by patent reviewers). It was granted before the observation that NNZ-2591 limited dendrite growth on synapse, which it thought to be part of the cause of Alzheimer’s disease.
If Alzheimer’s disease is added to the condition list, then NNZ-2591 will have a much wider application amongst the aging population.
The US 2014 patent for conditions for which NNZ-2591 may be...
-
- There are more pages in this discussion • 461 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.47 |
Change
-1.120(7.18%) |
Mkt cap ! $1.849B | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.40 | $14.40 | $9.160M | 624.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $14.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.55 | 1764 | 2 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |